STUDY NAME

DZ SITE

STUDY Description

ARMS

# PTS

ALCHEMIST A081801

NSCLC

Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST-IO

Must have EGRF, ALK, PD-LI IHC local testing with no identified arrangements. Must have completely resected dz IB (>/= 4cm), II or IIIA NSCLC with negative margins. Patients with N2 Disease completely resected are eligible. However, patients with known N2 dz prior to surgery or ineligible.

Initial Therapy:

Arm A: 4 Cycles of Platinum doublet

With Observation afterwards.

Arm B: 4 Cycles of Platinum doublet with 17 cycles of Keytruda

EA5182

NSCLC

Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab vs. AZD9291 (Osimertinib) Alone as First Line Treatment for Patients with Metastatic EGRR-Mutant Non Small Cell Lung Cancer (NSCLC)

Arm A: Osimertinib 80 mg po daily

Arm B: Osimertinib 80 mg po daily + Bevacizumab 15 mg kg IV every 3 weeks

S2302

NSCLC

A Prospective Randomized Study of Ramucirumab + Pemrbolizumab vs. standard of care for participants previously treated with Immnotherapy for Stage IV or recurrent NSCLC

Arm A:   Investigator’s SOC

Arm B:  Ramucirumab + Pembrolizumab

NRG-GI008

Study provides Natera Kits free of charge to the patient

Stage III

CRC

Colon Adjuvant Chemotherapy based on Evaluation of Residucal Disease (Circulate-US) 

Cohort B – ctDNA positive
Stratification – Intended Chemo (5 FU vs. Xeloda)
Randomization

Arm 3 – mFOLFOX 6 or CAPOX for 6 months

Cohort A ctDNA-neg
Stratification- Stage IIIA vs IIIB
Intended chemo (5FU vs. Xeloda)
After Randomization:
Arm 1 FOLFOX6 for 3 – 6 months or CAPOX for 3 months.

MorphoSys
MOR208C414

Diffuse Large B Cell Lymphoma

Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second or third line therapy and not receiving autologous stem cell transplant

1

Arm A - Chemo + Cetuximab

Arm B - Chemo + Avastin

Arm C - Avastin + Atezolizumab